Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 614

1.

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J.

J Hepatol. 2013 Dec;59(6):1271-7. doi: 10.1016/j.jhep.2013.07.029. Epub 2013 Aug 6.

PMID:
23928403
2.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT.

JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189.

PMID:
25058218
3.

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.

Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB 3rd, Venook AP.

Ann Oncol. 2013 Jul;24(7):1900-7. doi: 10.1093/annonc/mdt109. Epub 2013 Mar 21.

4.

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH.

Cancer Chemother Pharmacol. 2013 May;71(5):1241-6. doi: 10.1007/s00280-013-2118-9. Epub 2013 Mar 9.

5.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
6.

A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.

Ooka Y, Chiba T, Ogasawara S, Arai K, Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O.

Invest New Drugs. 2014 Aug;32(4):723-8. doi: 10.1007/s10637-014-0077-6. Epub 2014 Mar 7.

PMID:
24599799
7.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

8.

Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.

Srimuninnimit V, Sriuranpong V, Suwanvecho S.

Asia Pac J Clin Oncol. 2014 Sep;10(3):255-60. doi: 10.1111/ajco.12191. Epub 2014 May 9.

PMID:
24810940
9.

Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Brade AM, Ng S, Brierley J, Kim J, Dinniwell R, Ringash J, Wong RR, Cho C, Knox J, Dawson LA.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):580-7. doi: 10.1016/j.ijrobp.2015.11.048. Epub 2015 Dec 17.

PMID:
26867886
10.

Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L, Campani D, Bartolozzi C, Lencioni R, Filipponi F.

Transplant Proc. 2014 Jan-Feb;46(1):241-4. doi: 10.1016/j.transproceed.2013.10.035.

PMID:
24507059
11.

[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].

Zhao P, Chen D, Chen W, Yin XY, Yang D, Liang LJ.

Zhonghua Wai Ke Za Zhi. 2012 Jun;50(6):514-7. Chinese.

PMID:
22943944
12.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8.

13.

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT.

Aliment Pharmacol Ther. 2013 Jan;37(1):62-73. doi: 10.1111/apt.12132. Epub 2012 Nov 8.

14.

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD.

Cancer Chemother Pharmacol. 2014 Jan;73(1):181-9. doi: 10.1007/s00280-013-2339-y. Epub 2013 Nov 5.

15.

Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.

Abdel-Rahman O, Elsayed ZA.

Dig Dis Sci. 2013 Dec;58(12):3389-96. doi: 10.1007/s10620-013-2872-x. Epub 2013 Sep 18. Review.

PMID:
24046163
16.

Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.

Amato RJ, Flaherty AL, Stepankiw M.

Clin Genitourin Cancer. 2012 Mar;10(1):26-31. doi: 10.1016/j.clgc.2011.11.002. Epub 2011 Dec 13.

PMID:
22169794
17.

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.

J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.

18.

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB.

JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672.

PMID:
21081728
19.

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z.

Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.

PMID:
19095497
20.

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo W, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY.

Clin Cancer Res. 2014 Dec 1;20(23):5976-85. doi: 10.1158/1078-0432.CCR-13-3445. Epub 2014 Oct 7.

Items per page

Supplemental Content

Write to the Help Desk